Thermo Fisher Scientific’s PPD clinical research arm announced a strategic partnership with Datavant to enable privacy‑preserving tokenization and linkage of de‑identified clinical trial data with broad real‑world data sources. The collaboration will connect PPD datasets to Datavant’s network spanning 350+ RWD partners and tens of thousands of hospitals and clinics. Thermo Fisher said the integration will support RWD enrichment of randomized trials, registry linking, and bespoke evidence generation to improve trial design, recruitment, and external control construction. Datavant’s encrypted token technology will allow retrieval of consented electronic medical record data where permitted. The move reflects increasing demand for interoperable RWD to bolster regulatory and commercial evidence generation and to accelerate pragmatic and hybrid clinical development approaches.